ERMIUM THERAPEUTICS

In 2019, Domain Therapeutics, invested €3M ($3.2M) in Ermium Therapeutics.

Founded in June 2019 by Dr Jean-Philippe Herbeuval, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo, the Paris-based company, focuses on the development of an innovative class of immunomodulators targeting a GPCR, the chemokine CXCR4 receptor, for the treatment of autoimmune diseases.